SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter-2 (SGLT2) inhibitors were firstly authorized for the treatment of type 2 diabetes mellitus, but subsequently dapagliflozin and empagliflozin also for the treatment of heart failure with reduced ejection fraction based on their favorable cardiovascular outcomes (Mascolo et al., 2022b).